-
EP3548061
European procedure
Extract from the Register of European Patents
EP About this file: EP3548061
| EP3548061 - TREATMENT OF NEUROLOGICAL DISEASES [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 16.07.2021 Database last updated on 31.08.2024 | |
| Former | The patent has been granted Status updated on 07.08.2020 | ||
| Former | Grant of patent is intended Status updated on 20.04.2020 | ||
| Former | Request for examination was made Status updated on 06.09.2019 | ||
| Former | The international publication has been made Status updated on 16.06.2018 | ||
| Former | unknown Status updated on 19.12.2017 | Most recent event Tooltip | 16.07.2021 | No opposition filed within time limit | published on 18.08.2021 [2021/33] | Applicant(s) | For all designated states Lancaster University Business Enterprises Limited University House Bailrigg Lancaster LA1 4YW / GB | [2019/41] | Inventor(s) | 01 /
HÖLSCHER, Christian Lancaster University Furness College Lancaster Lancashire LA1 4YQ / GB | [2019/41] | Representative(s) | Høiberg P/S Adelgade 12 1304 Copenhagen K / DK | [2019/41] | Application number, filing date | 17811693.5 | 04.12.2017 | [2019/41] | WO2017GB53655 | Priority number, date | GB20160020611 | 05.12.2016 Original published format: GB 201620611 | [2019/41] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2018104718 | Date: | 14.06.2018 | Language: | EN | [2018/24] | Type: | A1 Application with search report | No.: | EP3548061 | Date: | 09.10.2019 | Language: | EN | The application published by WIPO in one of the EPO official languages on 14.06.2018 takes the place of the publication of the European patent application. | [2019/41] | Type: | B1 Patent specification | No.: | EP3548061 | Date: | 09.09.2020 | Language: | EN | [2020/37] | Search report(s) | International search report - published on: | EP | 14.06.2018 | Classification | IPC: | A61K38/00, A61P21/00, A61P25/14, A61P25/16, A61P25/28, C07K14/605, C07K14/00, A61P25/00, A61P25/02, A61P25/24, A61P25/08 | [2020/18] | CPC: |
C07K14/00 (EP,KR,RU);
A61K38/22 (RU);
C07K14/605 (EP,KR,RU,US);
A61K38/26 (RU);
A61K47/542 (RU,US);
A61P21/00 (EP,RU);
A61P25/00 (EP,KR);
A61P25/02 (EP);
A61P25/08 (EP);
A61P25/14 (EP);
A61P25/16 (EP,US);
A61P25/18 (RU);
A61P25/24 (EP);
A61P25/28 (EP,KR,RU,US);
A61P43/00 (EP);
|
| Former IPC [2019/41] | A61K38/22, A61K38/26, C07K14/605, C07K14/00 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2019/41] | Extension states | BA | Not yet paid | ME | Not yet paid | Validation states | MA | Not yet paid | MD | Not yet paid | TN | Not yet paid | Title | German: | BEHANDLUNG VON NEUROLOGISCHEN ERKRANKUNGEN | [2019/41] | English: | TREATMENT OF NEUROLOGICAL DISEASES | [2019/41] | French: | TRAITEMENT DE MALADIES NEUROLOGIQUES | [2019/41] | Entry into regional phase | 21.06.2019 | National basic fee paid | 21.06.2019 | Designation fee(s) paid | 21.06.2019 | Examination fee paid | Examination procedure | 02.10.2018 | Request for preliminary examination filed International Preliminary Examining Authority: EP | 21.06.2019 | Examination requested [2019/41] | 21.06.2019 | Date on which the examining division has become responsible | 21.01.2020 | Amendment by applicant (claims and/or description) | 21.04.2020 | Communication of intention to grant the patent | 30.07.2020 | Fee for grant paid | 30.07.2020 | Fee for publishing/printing paid | 30.07.2020 | Receipt of the translation of the claim(s) | Opposition(s) | 10.06.2021 | No opposition filed within time limit [2021/33] | Fees paid | Renewal fee | 11.12.2019 | Renewal fee patent year 03 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | AL | 09.09.2020 | [2021/26] | Cited in | International search | [Y]WO2013164483 (ZEALAND PHARMA AS [DK]) [Y] 1-28 * page 47 - page 49; claims 1-67 *; | [Y]WO2013192129 (UNIV INDIANA RES & TECH CORP [US]) [Y] 1-28 * SEQ ID 66;; claims 1-121 *; | [Y]US2016015788 (HOLSCHER CHRISTIAN [GB]) [Y] 1-28 * claims 1-20 *; | [Y] - JI CHENHUI ET AL, "A novel dual GLP-1 and GIP receptor agonist is neuroprotective in the MPTP mouse model of Parkinson's disease by increasing expression of BNDF", BRAIN RESEARCH, ELSEVIER, AMSTERDAM, NL, (20151011), vol. 1634, doi:10.1016/J.BRAINRES.2015.09.035, ISSN 0006-8993, pages 1 - 11, XP029449878 [Y] 1-28 * page 5 - page 8 * DOI: http://dx.doi.org/10.1016/j.brainres.2015.09.035 | [Y] - VERSPOHL ET AL, "Novel therapeutics for type 2 diabetes: Incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors", PHARMACOLOGY AND THERAPEUTICS, ELSEVIER, GB, vol. 124, no. 1, doi:10.1016/J.PHARMTHERA.2009.06.002, ISSN 0163-7258, (20091001), pages 113 - 138, (20090621), XP026501107 [Y] 1-28 * page 124; figure 2 * DOI: http://dx.doi.org/10.1016/j.pharmthera.2009.06.002 |